Novo Nordisk Pharmatech

News

Novo Nordisk shares fall further

Novo Nordisk slides further on US competition, new CEO concerns

Pedersen and Maggie Fick COPENHAGEN (Reuters) -Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs in the United States, a day after a profit warning and the naming of a new CEO prompted investors to wipe $70 billion off the drugmaker's value.

Seeking Alpha · 8h

Novo Nordisk: Catch That Falling Knife

Novo Nordisk stock drops 20%, but strong fundamentals, growth segments, and R&D pipeline make it an undervalued opportunity.

CBS News on MSN · 1d

Novo Nordisk shares fall 20% after company names new CEO and lowers its financial outlook

Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs.

Ozempic maker Novo Nordisk has its worst day since Black Monday

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

NVO stock: Why did Novo Nordisk shares drop 20% today—and who is Maziar Mike Doustdar?

Partially a result, Novo Nordisk has steadily declined since last summer. Over the past year, NVO shares are down more than ...

ABC News1mon

Wegovy maker ends partnership with Hims & Hers - ABC News

Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for patients who have a prescription for the medication but no insurance ...

The Motley Fool2mon

Novo Nordisk's 52% Plunge: Is the Company Fumbling Its Leadership in ...

Novo Nordisk has an estimated 62% market share of the GLP-1 agonist market, with archrival Eli Lilly accounting for another 35%. Investors are looking ahead to next-generation drugs that could ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results